CVI Holdings’s Dianthus Therapeutics DNTH Stock Holding History

CVI Holdings’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-25,880	Closed	-$3.11M	–	94
2020 Q2	$3.11M	Buy	+25,880	New	+$3.65M	1.15%	22

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CVI Holdings's DNTH Position: Q3 2020 in Review

CVI Holdings sold out of Dianthus Therapeutics (DNTH) in Q3 2020, closing a stake of 25,880 shares — an estimated $3.11M sold.

CVI Holdings first reported a position in DNTH in Q2 2020 and held it in 1 quarter. The position peaked at $3.11M in Q2 2020. 94 funds tracked by Wall St. Rank hold DNTH as of Q3 2020.

CVI Holdings reported no remaining Dianthus Therapeutics position as of Q3 2020 after selling out during the quarter.
CVI Holdings sold 25,880 Dianthus Therapeutics shares in Q3 2020, an estimated $3.11M.
CVI Holdings first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 1 quarter.
CVI Holdings's Dianthus Therapeutics position peaked at $3.11M in Q2 2020.
94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2020.

Based on CVI Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.